EFFECTOR Therapeutics Analyst Ratings
EFFECTOR Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/24/2023 | 604.23% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
| 05/26/2023 | 885.92% | Stifel | $1.3 → $7 | Upgrades | Hold → Buy |
| 05/10/2023 | 674.65% | Credit Suisse | $7 → $5.5 | Maintains | Outperform |
| 03/09/2023 | 885.92% | Credit Suisse | $8 → $7 | Maintains | Outperform |
| 01/09/2023 | 40.85% | JMP Securities | $2 → $1 | Maintains | Market Outperform |
| 01/06/2023 | 1026.76% | Credit Suisse | $10 → $8 | Maintains | Outperform |
| 11/17/2022 | 181.69% | JMP Securities | $5 → $2 | Maintains | Market Outperform |
| 08/11/2022 | 604.23% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 03/17/2022 | 1871.83% | Credit Suisse | $16 → $14 | Maintains | Outperform |
| 01/25/2022 | 2153.52% | Credit Suisse | $20 → $16 | Maintains | Outperform |
| 01/25/2022 | 773.24% | Stifel | $20 → $6.2 | Downgrades | Buy → Hold |
| 01/25/2022 | 1026.76% | JMP Securities | $33 → $8 | Maintains | Market Outperform |
| 11/09/2021 | 2716.9% | Stifel | → $20 | Upgrades | Hold → Buy |
| 10/12/2021 | 2716.9% | Credit Suisse | → $20 | Initiates Coverage On | → Outperform |
| 10/04/2021 | 2716.9% | Mizuho | → $20 | Initiates Coverage On | → Buy |
| 09/21/2021 | 4547.89% | JMP Securities | → $33 | Initiates Coverage On | → Market Outperform |
| 09/20/2021 | 2716.9% | Stifel | → $20 | Initiates Coverage On | → Hold |
| 09/13/2021 | 6942.25% | Cantor Fitzgerald | → $50 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/24/2023 | 604.23% | HC Wainwright & Co. | → 5 美元 | 启动覆盖开启 | → 购买 |
| 05/26/2023 | 885.92% | Stifel | 1.3 美元 → 7 美元 | 升级 | 持有 → 买入 |
| 05/10/2023 | 674.65% | 瑞士信贷 | 7 美元 → 5.5 美元 | 维护 | 跑赢大盘 |
| 03/09/2023 | 885.92% | 瑞士信贷 | 8 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 01/09/2023 | 40.85％ | JMP 证券 | $2 → $1 | 维护 | 市场表现跑赢大盘 |
| 01/06/2023 | 1026.76% | 瑞士信贷 | 10 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 11/17/2022 | 181.69% | JMP 证券 | 5 美元 → 2 美元 | 维护 | 市场表现跑赢大盘 |
| 08/11/2022 | 604.23% | JMP 证券 | 8 美元 → 5 美元 | 维护 | 市场表现跑赢大盘 |
| 03/17/2022 | 1871.83% | 瑞士信贷 | 16 美元 → 14 美元 | 维护 | 跑赢大盘 |
| 01/25/2022 | 2153.52% | 瑞士信贷 | 20 美元 → 16 美元 | 维护 | 跑赢大盘 |
| 01/25/2022 | 773.24% | Stifel | 20 美元 → 6.2 美元 | 降级 | 买入 → 持有 |
| 01/25/2022 | 1026.76% | JMP 证券 | 33 美元 → 8 美元 | 维护 | 市场表现跑赢大盘 |
| 2021 年 9 月 11 日 | 2716.9% | Stifel | → 20 美元 | 升级 | 持有 → 买入 |
| 2021 年 12 月 10 日 | 2716.9% | 瑞士信贷 | → 20 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2021 年 4 月 10 日 | 2716.9% | 瑞穗 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 09/21/2021 | 4547.89% | JMP 证券 | → 33 美元 | 启动覆盖开启 | → 市场跑赢大盘 |
| 09/20/2021 | 2716.9% | Stifel | → 20 美元 | 启动覆盖开启 | → 按住 |
| 09/13/2021 | 6942.25% | 坎托·菲茨杰拉德 | → 50 美元 | 启动覆盖开启 | → 超重 |
What is the target price for eFFECTOR Therapeutics (EFTR)?
Effector Therapeutics（EFTR）的目标价格是多少？
The latest price target for eFFECTOR Therapeutics (NASDAQ: EFTR) was reported by HC Wainwright & Co. on August 24, 2023. The analyst firm set a price target for $5.00 expecting EFTR to rise to within 12 months (a possible 604.23% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年8月24日公布了Effector Therapeutics（纳斯达克股票代码：EFTR）的最新目标股价。该分析公司将目标股价定为5.00美元，预计EFTR将在12个月内上涨至604.23％（可能上涨604.23％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for eFFECTOR Therapeutics (EFTR)?
Effector Therapeutics（EFTR）的最新分析师评级是多少？
The latest analyst rating for eFFECTOR Therapeutics (NASDAQ: EFTR) was provided by HC Wainwright & Co., and eFFECTOR Therapeutics initiated their buy rating.
Effector Therapeutics（纳斯达克股票代码：EFTR）的最新分析师评级由HC Wainwright & Co. 提供，Effector Therapeutics启动了买入评级。
When is the next analyst rating going to be posted or updated for eFFECTOR Therapeutics (EFTR)?
Effector Therapeutics（EFTR）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of eFFECTOR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for eFFECTOR Therapeutics was filed on August 24, 2023 so you should expect the next rating to be made available sometime around August 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括阅读公开财务报表、与Effector Therapeutics的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Effector Therapeutics的最后一次评级是在2023年8月24日提交的，因此你应该预计下一个评级将在2024年8月24日左右公布。
Is the Analyst Rating eFFECTOR Therapeutics (EFTR) correct?
分析师评级 Effector Therapeutics (EFTR) 是否正确？
While ratings are subjective and will change, the latest eFFECTOR Therapeutics (EFTR) rating was a initiated with a price target of $0.00 to $5.00. The current price eFFECTOR Therapeutics (EFTR) is trading at is $0.71, which is within the analyst's predicted range.
虽然评级是主观的，并且会发生变化，但最新的Effector Therapeutics（EFTR）评级最初的目标价为0.00美元至5.00美元。Effector Therapeutics（EFTR）目前的交易价格为0.71美元，在分析师的预测区间内。